These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37151179)
21. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
22. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. Zekeridou A; Majed M; Heliopoulos I; Lennon VA Thorac Cancer; 2019 Apr; 10(4):1001-1004. PubMed ID: 30810271 [TBL] [Abstract][Full Text] [Related]
23. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. Valencia-Sanchez C; Zekeridou A Front Neurol; 2021; 12():642800. PubMed ID: 33897597 [TBL] [Abstract][Full Text] [Related]
24. Immune-mediated diseases involving central and peripheral nervous systems. Leboyan A; Esselin F; Bascou AL; Duflos C; Ion I; Charif M; Castelnovo G; Carra-Dalliere C; Ayrignac X; Kerschen P; Chbicheb M; Nguyen L; Maria ATJ; Guilpain P; Carriere M; de Champfleur NM; Vincent T; Jentzer A; Labauge P; Devaux JJ; Taieb G Eur J Neurol; 2023 Feb; 30(2):490-500. PubMed ID: 36366904 [TBL] [Abstract][Full Text] [Related]
31. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812 [TBL] [Abstract][Full Text] [Related]
32. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495 [TBL] [Abstract][Full Text] [Related]
34. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151 [TBL] [Abstract][Full Text] [Related]
35. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy. Kang K; Zheng K; Zhang Y J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750 [TBL] [Abstract][Full Text] [Related]